Genovate Biotechnology Co., Ltd. (4130) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Genovate Biotechnology Co., Ltd. (4130:TWSE), powered by AI.

Current Price
$34.05
Sector
Healthcare
What is the Genovate Biotechnology Co., Ltd. stock price forecast?

Genovate Biotechnology Co., Ltd. is currently trading at $34.05. View real-time AI analysis on Alpha Lenz.

What is Genovate Biotechnology Co., Ltd. insider trading activity?

View the latest insider trading data for Genovate Biotechnology Co., Ltd. on Alpha Lenz.

What is Genovate Biotechnology Co., Ltd.'s P/E ratio?

View Genovate Biotechnology Co., Ltd.'s valuation metrics on Alpha Lenz.

Genovate Biotechnology Co., Ltd.

NT$34.05
TWSE4130
Ask about Genovate Biotechnology Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Genovate Biotechnology Co., Ltd.'s ROE is 0.8%. Explore profitability and growth together.

Ask for details

Company Overview

Genovate Biotechnology Co., Ltd. is a healthcare company specializing in the research, development, manufacturing, and sale of pharmaceutical products. Its primary function is to provide a broad range of specialty drugs and active pharmaceutical ingredients targeting diseases caused by viruses and bacteria, with a portfolio that includes antimicrobial, anticancer, cardiovascular, alimentary tract, metabolic, dermatologic, musculoskeletal, nervous system, respiratory, and urinary system drugs. The company also develops controlled-release dosage forms and is active in the cosmetics segment as well as healthcare foods. Founded in 1982 and headquartered in Hsinchu, Taiwan, Genovate Biotechnology plays a significant role within the Taiwanese pharmaceutical and biotechnology sector, supporting both the domestic healthcare market and the ongoing development of new therapeutic products. By integrating clinical experimental services and technology exports into its business, the company enhances its market relevance and helps address a range of prevalent medical needs across multiple therapeutic areas.

SectorHealthcare
IndustryBiotechnology
Employees191

Company Statistics

(FY 2025)

Profile

Market CapN/A
RevenueNT$492.41M
Shares Out0.00
Employees191

Margins

Gross35.95%
EBITDA10.74%
Operating1.40%
Pre-Tax2.73%
Net2.37%

Valuation

P/EN/A
P/BN/A
EV/SalesN/A
EV/EBITDAN/A
P/FCFN/A

Growth (CAGR)

Rev 3Yr3.92%
Rev 5Yr0.82%
Op Inc 3YrN/A
Op Inc 5Yr-29.42%
Net Inc 3YrN/A
Net Inc 5Yr-21.32%

Returns

ROA0.75%
ROE0.83%
ROIC0.91%

Financial Health

Cash & Cash EquivalentsNT$169.04M
Net DebtNT$-42.99M
Debt/Equity9.13%
Interest CovN/A
Ask Alpha Chat

Frequently Asked Questions

Alpha Lenz
Singapore
CEO: Kyungtae Kim | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2025 Treasurer. All rights reserved.
Genovate Biotechnology Co., Ltd. (Healthcare) Stock Forecast & Analysis $34.05 | Alpha Lenz